Hepatotoxicity, while rare, is a serious potential adverse effect of Diflucan.

Diflucan achieves good penetration into peritoneal fluid.

Invasive candidiasis treatment duration is guided by resolution of symptoms and bloodstream clearance.

Diflucan is used in some protocols for antifungal lock therapy for catheter-related infections.

Efficacy in peritoneal candidiasis is supported by good peritoneal penetration.

Diflucan is a model of predictable pharmacokinetics within the azole class.

A post-antimicrobial effect has been demonstrated against some Candida species.

Generic fluconazole has made Diflucan’s benefits accessible at a lower cost.

Often compared to itraconazole, with a more predictable pharmacokinetic profile but narrower spectrum.

Its legacy is its role in making systemic antifungal therapy outpatient-friendly and accessible.